

Isolation of a Human Myocardial Cytosolic Phospholipase A₂ Isoform

Fast Atom Bombardment Mass Spectroscopic and Reverse-Phase High Pressure Liquid Chromatography Identification of Choline and Ethanolamine Glycerophospholipid Substrates

Stanley L. Hazen, Curtis R. Hall, David A. Ford, and Richard W. Gross

Division of Bioorganic Chemistry and Molecular Pharmacology, Washington University School of Medicine, St. Louis, Missouri 63110

Abstract

Recent studies have demonstrated the existence of a novel family of calcium-independent plasmalogen-selective phospholipases A₂ in canine myocardium that have been implicated as enzymic mediators of ischemic membrane damage. We now report that human myocardium contains two functionally distinct isoforms of cytosolic calcium-independent phospholipase A₂. The major cytosolic phospholipase A₂ isoform preferentially hydrolyzes plasmalogen substrate, possesses a pH optimum of 7.0, and is chromatographically resolvable from a minor cytosolic calcium-independent phospholipase A₂ isoform that hydrolyzes plasmenylcholine and phosphatidylcholine substrates at similar rates and possesses a pH optimum of 8.5. The major cytosolic calcium-independent phospholipase A₂ isoform was identified as a 40-kD polypeptide after its 182,000-fold purification by sequential column chromatographies to a final specific activity of 67 μmol/mg · min. The purified 40-kD human myocardial phospholipase A₂ preferentially hydrolyzes plasmalogens containing arachidonic acid at the *sn*-2 position. Both reverse-phase HPLC and fast atom bombardment mass spectroscopic analysis of human myocardial ethanolamine and choline glycerophospholipids demonstrated that plasmenylethanolamine and plasmenylcholine molecular species containing arachidonic acid at the *sn*-2 position are prominent constituents of human myocardium. Collectively, these results identify and characterize the major human myocardial cytosolic calcium-independent phospholipase A₂ activity, demonstrate the presence of functionally distinct human myocardial cytosolic calcium-independent phospholipase A₂ isoforms, and document the abundance of arachidonoylated plasmalogen molecular species in human myocardium that serve as substrates. (*J. Clin. Invest.* 1993. 91:2513–2522.) **Key words:** arachidonic acid • myocardial ischemia • plasmalogens • phospholipase A₂ • phospholipids

Introduction

Phospholipases are critical proximal enzymic mediators of signal transduction processes in mammalian cells because they catalyze the regiospecific cleavage of the chemical precursors of

biologically active lipid-derived second messengers (cf. references 1–4). The highly regulated and specific activation of intracellular phospholipases facilitates the appropriate adaptation of cellular function to external perturbations. However, the inappropriate activation of these signal transducers has been recognized as an important biochemical mechanism contributing to the pathophysiologic sequelae of several disease states including inflammation, atherosclerosis, and ischemic membrane dysfunction (cf. references 5–9). In myocardium, accelerated phospholipid catabolism resulting from the activation of phospholipases A₂ during ischemia has been implicated as the biochemical mechanism precipitating electrophysiologic dysfunction and myocytic cellular necrosis during myocardial infarction (e.g., references 10–15). Accordingly, recent attention has focused on the identification and characterization of enzymes mediating phospholipid catabolism in myocardium from a wide variety of mammalian species and the elucidation of the molecular identities of individual phospholipid constituents that serve as their substrates during an ischemic insult. Although substantial insights into some of the characteristics of enzymes mediating phospholipid catabolism in several species of mammalian myocardium have been made (13, 16–21), little information is presently available on the detailed chemical characteristics of human myocardial phospholipase(s) A₂, the multiplicity of different phospholipases A₂ present in human myocardium or the chemical identities of the individual phospholipid constituents present in human myocardium which serve as their lipid substrates.

Prior studies of the individual molecular species of phospholipids present in mammalian myocardium obtained from several species demonstrated the unanticipated finding that some subcellular membranes (e.g., sarcolemma and sarcoplasmic reticulum) were predominantly composed of plasmalogen molecular species containing arachidonic acid at the *sn*-2 position (22, 23). The potential physiologic and pathophysiologic significance of the high plasmalogen content present in these critical myocardial subcellular membrane compartments was underscored by the identification of a calcium-independent phospholipase A₂ in canine myocardium which selectively utilized plasmalogen substrate (17). It is now well established that myocardial plasmalogen content has substantial interspecies variation (22–27), and that a diverse array of phospholipases A₂ are present in mammalian tissues (13, 16, 17, 18, 20, 21). To delineate the individual molecular species of phospholipids present in human myocardium and to characterize the enzymes mediating their catalysis, human myocardial cytosolic phospholipase A₂ was purified from fresh human myocardium obtained from transplant recipients and detailed analyses of individual human myocardial phospholipid molecular species were performed. We now report the purification of the major human myocardial cytosolic calcium-independent phospholipase A₂ activity to apparent homogeneity, identify the presence

Address reprint requests to Dr. Richard W. Gross, Division of Bioorganic Chemistry and Molecular Pharmacology, Washington University School of Medicine, 660 South Euclid, Box 8020, St. Louis, MO 63110.

Received for publication 30 October 1992 and in revised form 28 January 1993.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/93/06/2513/10 \$2.00

Volume 91, June 1993, 2513–2522

of cytosolic calcium-independent phospholipase A₂ isoforms with distinct physical and kinetic characteristics, and demonstrate that the major observable cytosolic phospholipase A₂ isoform preferentially catalyzes the hydrolysis of plasmenylcholine substrate containing arachidonic acid at the *sn*-2 position which is an abundant phospholipid constituent of human myocardium.

Methods

Isolation of human myocardial cytosolic calcium-independent phospholipase A₂. Human myocardial cytosolic calcium-independent phospholipase A₂ was isolated utilizing a modification of the scheme employed for the purification of canine cytosolic phospholipase A₂ (20, 28). Briefly, fresh human myocardium obtained from transplant recipients suffering from end-stage ischemic cardiomyopathy was placed in ice-cold isotonic saline solution. Left ventricular tissue was trimmed of epicardial fat and visible fibrotic lesions, weighed and placed in homogenization buffer (10 mM imidazole, 10 mM KCl, 0.25 M sucrose [grade 1], pH 7.8) at 25% wt/vol. All subsequent steps were performed at 4°C. Ventricular tissue was minced into small pieces with sharp surgical scissors and homogenized with three strokes of a loose-fitting Potter-Elvehjem apparatus (Fisher Scientific, Inc., St. Louis, MO) operated at 2,000 rpm. The cytosolic fraction was subsequently isolated by differential centrifugation as previously described (20). Briefly, crude myocardial homogenate was initially centrifuged at 10,000 *g*_{max} for 20 min and the upper layer of the supernatant containing visible lipid was gently removed by aspiration. The resultant supernatant was then centrifuged at 85,000 *g*_{max} for 60 min and the microsomal pellet was discarded.

Human myocardial cytosolic calcium-independent phospholipase A₂ was purified by sequential anion exchange, chromatofocusing, ATP-affinity, and Mono-Q chromatographies (20). Briefly, human myocardial cytosol was filtered through glass wool, dialyzed against 2 × 10 liter (8 h each) of buffer 1 (15 mM imidazole, 5 mM K[PO₄], 10% glycerol, pH 7.8) and loaded onto a preequilibrated DEAE-Sephacel column (5 × 5 cm, 2.5 ml/min). The column was washed with buffer 1 containing 1 mM DTT, and developed with a discontinuous step gradient of 0.2 M NaCl followed by 1 M NaCl in 10 mM imidazole, 10 mM KCl, 10% glycerol, 1 mM DTT, pH 8.0. Fractions containing the majority of phospholipase A₂ activity in the 0.2 M NaCl eluent were identified, pooled, and dialyzed against 20 liter of buffer 2 (10 mM imidazole, 10 mM KCl, 25% glycerol, 1 mM DTT, pH 8.0) for 15 h. The dialyzed DEAE-Sephacel 0.2 M NaCl eluent was next loaded onto a previously equilibrated PBE-94 (Pharmacia-LKB Biotechnology, Piscataway, NJ) chromatofocusing column (1.6 × 30 cm, 1.5 ml/min), which was developed with a pH gradient generated by application of buffer composed of 10% PB96, 5% PB74, 25% glycerol, 1 mM DTT, pH 5.4. Fractions containing the majority of phospholipase A₂ activity were immediately identified, pooled, and applied to a 1 × 1 cm N⁶-[(6-aminohexyl) carbamoyl-methyl]ATP-agarose affinity column previously equilibrated in buffer 3 (10 mM imidazole, 25% glycerol, 1 mM DTT, pH 8.3). After loading, the affinity column was washed with buffer 3, buffer 3 containing 10 mM AMP (which removes the majority of bound proteins), buffer 3 alone (to remove UV absorbing AMP) and, finally, buffer 3 containing 1 mM ATP (which eluted human myocardial calcium-independent phospholipase A₂ in near quantitative yield). The active fractions from the ATP-agarose affinity column eluent were then applied to an HR5/5 Mono-Q column (Pharmacia-LKB Biotechnology) previously equilibrated in buffer 4 (20 mM imidazole, 25% glycerol, 1 mM DTT, pH 8.3) and phospholipase A₂ was eluted utilizing a discontinuous NaCl gradient (0–500 mM).

Preparation of synthetic phospholipids. Homogeneous 16:0,[³H] 18:1 (1.4 × 10⁶ dpm/nmol) and 16:0,[³H]20:4 (6.7 × 10⁵ dpm/nmol) plasmenylcholine and phosphatidylcholine molecular species were prepared by condensation of dicyclohexylcarbodiimide-generated ³H-fatty acid anhydride with the appropriate reverse-phase HPLC-purified lysophospholipid as previously described (29). Polar head

group-labeled plasmenylcholine (2.0 × 10⁵ dpm/nmol) was synthesized similarly utilizing ([³H]Me-choline)lysoplasmenylcholine and oleoyl anhydride. ([³H]Me-choline)lysoplasmenylcholine was prepared by exhaustive methylation of reverse-phase purified lysoplasmenylethanolamine (30) utilizing [³H]CH₃I with benzyltrimethyl ammonium chloride as catalyst (31). Each radiolabeled choline glycerophospholipid was initially purified by preparative TLC and subsequently purified by Partisil SCX-HPLC chromatography (P. J. Colbert, Inc., St. Louis, MO) as previously described (20, 29). To facilitate direct kinetic comparisons between diacyl and vinyl ether subclasses, radiolabeled molecular species of identical specific activities were synthesized utilizing common preparations of freshly synthesized radiolabeled fatty acid anhydride as reagent. The purity and regioselectivity of each radiolabeled synthetic product was confirmed by TLC in two solvent systems, straight-phase HPLC, comigration with authentic standards on reverse-phase HPLC, as well as isolation and quantitation of reaction products generated by either *Naja naja* phospholipase A₂ or *Bacillus cereus* phospholipase C catalysis as previously described (20).

Enzyme assays. Phospholipase A₂ activity in cytosol and in column chromatographic fractions was routinely assayed by incubating enzyme with 2 μM 16:0,[³H] 18:1 plasmenylcholine introduced by ethanolic injection (10 μl) into assay buffer (final conditions: 100 mM Tris, 4 mM EGTA, 4 mM EDTA, pH 7.0) at 37°C for 5 min in a final volume of 210 μl unless otherwise indicated. Reactions were quenched with butanol, and radiolabeled products were subsequently isolated and quantified by TLC and scintillation spectrometry, respectively, as previously described (20). Kinetic assays for phospholipase A₂ activity were performed similarly except that incubations were performed for 60 s which resulted in linear reaction velocities with respect to both time and enzyme concentration for each substrate utilized. To facilitate direct comparisons, assays examining the properties of cytosolic phospholipase A₂ isoforms were performed under identical salt conditions by addition of appropriate amounts of buffer containing additional NaCl (i.e., final NaCl concentration in assays directly comparing phospholipase A₂ isoforms in Fig. 2 = 30 mM).

Identification of human myocardial choline and ethanolamine glycerophospholipid molecular species by reverse-phase HPLC and fast atom bombardment mass spectrometry. Human left ventricular tissue was trimmed of epicardial fat and visible fibrotic lesions were removed. The ventricular tissue was freeze clamped and pulverized at the temperature of liquid nitrogen. Human ventricular lipids were extracted by the method of Bligh and Dyer (32) and subsequently stored at –20°C under a nitrogen atmosphere in chloroform. Human myocardial choline and ethanolamine glycerophospholipids from Bligh and Dyer extracts were purified by straight-phase HPLC employing an Ultrasphere Si column (4.6 × 250 mm; 5 μm particles) and gradient elution with hexane/isopropanol/water (48.5/48.5/3, vol/vol/vol) as the initial mobile phase and hexane/isopropanol/water (46.5/46.5/7, vol/vol/vol) as the final mobile phase as described previously (33). Column eluents were evaporated under a nitrogen stream and the purified choline and ethanolamine glycerophospholipids were resuspended and stored at –20°C in 2 ml each of chloroform under a nitrogen atmosphere.

Individual molecular species of human myocardial choline and ethanolamine glycerophospholipids were resolved after preparation of their monobenzoate diradyl glycerol derivatives as previously described (34). In brief, 1 mg of either straight-phase HPLC-purified human myocardial choline or ethanolamine glycerophospholipids was dried under a nitrogen stream and resuspended in ferrous sulfate-washed diethyl ether before incubation with *Bacillus cereus* phospholipase C (20 U) for 60 min at 22°C. The resultant diradyl glycerols were directly benzoylated with benzoic anhydride utilizing *N,N*-dimethyl-4-aminopyridine as catalyst (34). Monobenzoate diradyl glycerol derivatives of human myocardial choline or ethanolamine glycerophospholipids were purified by thin layer chromatography utilizing silica G TLC plates and a mobile phase comprised of hexane/diethyl ether/ammonium hydroxide (85/15/1, vol/vol/vol). Regions of the TLC plate corresponding to the purified monobenzoate diradyl glycerols were

scraped into test tubes, extracted with chloroform/methanol (1/1, vol/vol), dried under a stream of nitrogen gas and resuspended in 50 μ l of acetonitrile/isopropanol (85/15, vol/vol). Individual monobenzoate diradyl glycerol derivatives of human myocardial choline or ethanolamine glycerophospholipid molecular species were subsequently resolved by reverse-phase HPLC utilizing an octadecyl silica stationary phase and an acetonitrile/isopropanol (85/15, vol/vol) mobile phase at a flow rate of 1 ml/min. Identification of each monobenzoate diradyl glycerol molecular species derived from human myocardial choline or ethanolamine glycerophospholipids was facilitated by collecting column eluents from each UV absorbing peak (231 nm), drying eluents under nitrogen and analyzing their acid methanolysis derivatives by capillary gas chromatography. The relative mass distribution of individual molecular species of straight-phase HPLC purified human myocardial choline or ethanolamine glycerophospholipids was also independently determined by fast atom bombardment mass spectrometry as previously described (22).

Sources of materials and miscellaneous procedures. Bolton-Hunter iodination, SDS-PAGE, 125 I autoradiography, and protein determinations were performed as previously described (20). $[^3\text{H}]\text{CH}_3$ was obtained from Amersham Corp., Arlington Heights, IL. All other radiolabeled materials were purchased from Dupont-New England Nuclear, Boston, MA. Oleic and arachidonic acids were obtained from NuChek Prep, Inc. (Elysian, MN), while all other lipids were obtained from Avanti Polar Lipids (Alabaster, AL). DEAE-Sephacel, PBE-94, PB74, PB96, and Mono-Q columns were purchased from Pharmacia LKB Biotechnology, Inc. Nucleotides of the highest quality (i.e., vanadate-free where possible) were obtained from either Boehringer Mannheim Biochemicals, Indianapolis, IN or Sigma Chemical Co., St. Louis, MO. Most other reagents were obtained from either Aldrich Chemical Co., Milwaukee, WI or Sigma Chemical Co.

Results

Chromatographic resolution and kinetic characterization of human myocardial cytosolic phospholipase A_2 isoforms. To characterize the polypeptide(s) mediating phospholipase A_2 activity in human myocardial cytosol, the protein constituents in dialyzed cytosol were initially fractionated by anion exchange chromatography. The majority of phospholipase A_2 activity was adsorbed to the stationary phase under the conditions employed and was eluted by application of buffer containing 200 mM NaCl. However, a second peak of phospholipase A_2 activity required higher salt concentrations for elution (peak 2) (Fig. 1). Phospholipase A_2 activity in peak 1 represented $\sim 90\%$ of recovered activity and was relatively stable while the enzymatic activity in peak 2 accounted for $\sim 10\%$ of eluted activity and was markedly labile under the conditions employed. No calcium-dependent phospholipase A_2 activity in the cytosol or in column eluents was detectable under the conditions employed.

To determine if the polypeptide(s) catalyzing calcium-independent phospholipase A_2 activity in peaks 1 and 2 (Fig. 1) possessed similar physical and kinetic characteristics, the substrate specificities, calcium requirements, and pH profiles of enzymatic activity in each peak were determined. Phospholipase A_2 activity in peak 1 was calcium-independent, neutral active (pH optimum 7.0) and possessed a threefold selectivity for hydrolysis of 16:0, $[^3\text{H}]$ 18:1 plasmenylcholine substrate over 16:0, $[^3\text{H}]$ 18:1 phosphatidylcholine substrate (Fig. 2). Phospholipase A_2 activity in peak 2 was also calcium-independent but, in sharp contrast, it possessed a basic pH optimum (pH 8.5) and hydrolyzed phosphatidylcholine and plasmenylcholine substrates at similar rates (Fig. 2). The regioselectivity of phospholipase A_2 activities in peaks 1 and 2 was confirmed




Figure 1. DEAE-Sephacel chromatography of human myocardial cytosolic calcium-independent phospholipases A_2 . Human myocardial cytosol was dialyzed and loaded onto a DEAE-Sephacel column, and phospholipase A_2 activity was eluted with a discontinuous NaCl gradient as described in Methods. Aliquots of column eluents were assayed by quantifying radiolabeled fatty acid released (\bullet) from 16:0, $[^3\text{H}]$ 18:1 plasmenylcholine as described in Methods. (—) UV absorbance at 280 nm.

by demonstration of the concomitant release of *sn*-2 radiolabeled fatty acid and polar head group labeled lysoplasmeylcholine from 16:0, $[^3\text{H}]$ 18:1 plasmenylcholine and 16:0, 18:1 ($[^3\text{H}]$ Me-choline) plasmenylcholine, respectively.

Purification of the major human myocardial phospholipase A_2 isoform. The polypeptide(s) catalyzing phospholipase A_2 activity in peak 1 was purified to apparent homogeneity by sequential chromatofocusing, affinity, and Mono-Q chromatographies. The lability of the polypeptide catalyzing phospholipase A_2 activity in peak 2 precluded further purification of




Figure 2. Comparison of human myocardial cytosolic phospholipase A_2 isoforms. Phospholipase A_2 activity in peak 1 (200 mM NaCl eluent) or peak 2 (1 M NaCl eluent) was assessed at the indicated pH by quantifying radiolabeled fatty acid release from 16:0, $[^3\text{H}]$ 18:1 plasmenylcholine or 16:0, $[^3\text{H}]$ 18:1 phosphatidylcholine in buffer containing 200 mM $\text{K}[\text{PO}_4]$, 4 mM EGTA, 4 mM EDTA, pH 4.5–9.0, as described in Methods. Data are expressed as PK_1 : ^3H -fatty acid released from either 16:0, $[^3\text{H}]$ 18:1 plasmenylcholine (\bullet), or 16:0, $[^3\text{H}]$ 18:1 phosphatidylcholine (\circ).

PK_2 : ^3H -fatty acid released from either 16:0, $[^3\text{H}]$ 18:1 plasmenylcholine (\blacktriangle), or 16:0, $[^3\text{H}]$ 18:1 phosphatidylcholine (\triangle). Data points represent the mean of duplicate determinations.




Figure 3. Chromatofocusing profile of human myocardial cytosolic calcium-independent phospholipase A₂. DEAE-Sephacel fractions possessing the majority of phospholipase A₂ activity in the 200 mM NaCl eluent (PK₁) were dialyzed and applied to a chromatofocusing column, and phospholipase A₂ activity was eluted by the generation of a pH gradient as described in Methods. Phospholipase A₂ activity in aliquots of column eluents was assayed by quantifying radiolabeled fatty acid released from 16:0, [³H] 18:1 plasmenylcholine (●) as described in Methods. (—) UV absorbance at 280 nm; (▲) pH.





Figure 4. ATP affinity chromatography of human myocardial cytosolic calcium-independent phospholipase A₂. *Left:* Chromatofocusing fractions containing the majority of phospholipase A₂ activity were applied to an ATP-agarose column. The column was subsequently washed with equilibration buffer, buffer containing 10 mM AMP, and buffer alone for the indicated volumes. Phospholipase A₂ was eluted with buffer containing 1 mM ATP as described in Methods. Phospholipase A₂ activity in column chromatographic fractions was assessed utilizing 16:0, [³H] 18:1 plasmenylcholine substrate and released radiolabeled fatty acid (●) was isolated by TLC and quantified by scintillation spectrometry as described in Methods. *Right:* Aliquots from ATP affinity chromatography were boiled for 1 min in the presence of 100 mM 2-mercaptoethanol and 10% SDS, loaded onto a 10–15% gradient polyacrylamide gel, electrophoresed, and subsequently visualized by silver staining. L, V, AMP, and ATP refer to chromatographic fractions from

this fraction in our hands. Phospholipase A₂ activity in peak 1 was focused into a major peak eluting at pI 6.9 during chromatofocusing which was reproducibly preceded by a smaller peak of activity eluting between pH 7.6–7.7 (Fig. 3). Further characterization of the pH optimum and choline glycerophospholipid subclass selectivity of the peak fraction from the major peak (pI 6.9) demonstrated the selective hydrolysis of vinyl ether containing choline glycerophospholipids at a pH optimum of 7.0. Interestingly, the earlier eluting peak preceding the elution of the major position of phospholipase A₂ activity hydrolyzed diacyl and vinyl ether containing choline glycerophospholipids at similar rates and possessed a pH optimum of 9 (similar to the behavior of peak 2 from the DEAE-Sephacel column).

Chromatofocusing fractions possessing the majority of phospholipase A₂ activity were pooled and subsequently loaded onto an ATP-agarose affinity matrix as described in Methods. Phospholipase A₂ activity selectively and quantitatively adsorbed to the ATP-affinity matrix while the majority of other proteins eluted in the void volume (Fig. 4). Application of buffer containing 10 mM AMP failed to elute substantive amounts of phospholipase A₂ activity even though the large majority of proteins which were adsorbed onto the affinity matrix were eluted (Fig. 4). Subsequent application of buffer containing 1 mM ATP resulted in recovery of 85% of applied phospholipase A₂ activity with a 120-fold purification of human myocardial cytosolic phospholipase A₂ activity achieved in a single step (Table I, Fig. 4). Human myocardial cytosolic calcium-independent phospholipase A₂ was subsequently purified to apparent homogeneity by application of the ATP-agarose eluent to an HR5/5 Mono-Q column with subsequent elution utilizing a shallow discontinuous NaCl gradient

the load, void, AMP eluent, and ATP eluent of the ATP-affinity column, respectively. The migration of molecular mass standards is shown on the right and the arrow indicates the 40-kD cytosolic phospholipase A₂.

Table 1. Human Myocardial Cytosolic Calcium-independent Phospholipase A₂ Purification Table

	Protein	Total activity	Specific activity	Purification	Yield
	mg	nmol/min	nmol/mg · min	-fold	%
Cytosol	963	356	0.37	1	100
DEAE-Sephadex					
Peak 1**	247	271	1.10	3.00	76
Peak 2‡	(66)	(36)	(0.54)	(1.5)	(10)
Chromatofocusing	7	189	27	73	53
ATP-agarose	0.05	160	3,200	8,650	45
Mono-Q	0.002	134	67,200	181,600	38

Human myocardial cytosolic calcium-independent phospholipase A₂ was purified by sequential DEAE, chromatofocusing, ATP-agarose, and Mono-Q chromatographies. Phospholipase A₂ activity in human myocardial cytosol and column chromatographic fractions was assayed utilizing 16:0, [³H]18:1 plasmalogen substrate as described in Methods. The only radiolabeled product detected was [³H]oleic acid, without detectable radiolabeled lysophospholipid, diglyceride, monoglyceride, or phosphatidate.

* 200 mM NaCl eluent.

‡ Subsequent purification of cytosolic phospholipase A₂ activity utilized peak 1 from DEAE-Sephadex chromatography.

§ 1 M NaCl eluent.

(Fig. 5). Collectively, this series of column chromatographic steps resulted in the 182,000-fold purification of the major human myocardial cytosolic calcium-independent phospholipase A₂ isoform in 38% yield to a final specific activity of 67 μmol/mg · min (Table 1).

SDS-PAGE and ¹²⁵I autoradiography. The purity of the phospholipase A₂ preparation was analyzed by SDS-PAGE and ¹²⁵I autoradiography after Bolton-Hunter iodination (Fig. 6). An intense band at 40 kD was observed in the most active fraction (fraction 13) from Mono-Q chromatography. Furthermore, the intensity of the 40-kD band precisely correlated with the relative amounts of phospholipase A₂ activity found in each fraction of Mono-Q column chromatographic eluent. The high




Figure 5. Mono-Q chromatography of human myocardial cytosolic calcium-independent phospholipase A₂. Active fractions from ATP affinity chromatography were pooled and loaded onto an HR5/5 fast protein liquid chromatography-Mono-Q column, and phospholipase A₂ was eluted utilizing a nonlinear NaCl gradient as described in Methods. Phospholipase A₂ activity was assessed utilizing 16:0, [³H]18:1 plasmalogen substrate, and radiolabeled fatty acid release (●) was quantified as described in Methods. (—) UV absorbance at 280 nm; (---) NaCl concentration. Arrows identify the elution of UV absorbing nucleotides AMP, ADP, and ATP.

sensitivity and dynamic range of the visualization method employed (¹²⁵I autoradiography), the high specific activity of the purified polypeptide (67 μmol/mg · min), as well as the concordant appearance and disappearance of the 40-kD band with phospholipase A₂ activity collectively demonstrate that the 40-kD polypeptide catalyzes human myocardial phospholipase A₂ activity.

Kinetic characterization of purified human myocardial phospholipase A₂. To determine the phospholipid class selectivity of human myocardial cytosolic calcium-independent phospholipase A₂, two types of kinetic experiments were performed. First, the initial velocity of phospholipase A₂ activity was determined as a function of substrate concentration utilizing either homogeneous phosphatidylcholine, phosphatidylinositol, or phosphatidylethanolamine containing radiolabeled arachidonic acid at the sn-2 position. Both phosphatidylcholine and phosphatidylinositol are present in the bilayer configuration at the assay temperature employed (i.e., 37°C), while phosphatidylethanolamine assumes an inverted hexagonal II




Figure 6. Elution of protein constituents from Mono-Q chromatography as revealed by ¹²⁵I autoradiography SDS-PAGE. Aliquots of the active fractions from fast protein liquid chromatography-Mono-Q chromatography were iodinated with Bolton-Hunter reagent, boiled for 1 min in the presence of 100 mM 2-mercaptoethanol and 10%

SDS, loaded onto a polyacrylamide slab gel, electrophoresed, fixed, dried, and subsequently visualized by ¹²⁵I autoradiography. Fraction numbers on the x-axis correspond to fractions from the Mono-Q column shown in Fig. 5.

configuration at this temperature (35). Utilizing these homogeneous systems, and highly purified human myocardial cytosolic phospholipase A₂ (Mono-Q eluent; 180,000-fold purified) phosphatidylethanolamine was the preferred substrate, yielding an apparent $V_{\max} = 194 \mu\text{mol}/\text{mg} \cdot \text{min}$ followed by phosphatidylcholine (apparent $V_{\max} = 71 \mu\text{mol}/\text{mg} \cdot \text{min}$) with modest hydrolysis manifest utilizing the highly negatively charged phosphatidylinositol bilayer substrate (apparent $V_{\max} = 8.4 \mu\text{mol}/\text{mg} \cdot \text{min}$). Furthermore, because the apparent affinity of purified phospholipase A₂ for either choline or ethanolamine glycerophospholipid substrate is approximately an order of magnitude greater than that for the corresponding inositol glycerophospholipid (i.e., apparent $K_m = 4 \mu\text{M}$ for phosphatidylcholine or phosphatidylethanolamine vs. $34 \mu\text{M}$ for phosphatidylinositol), the catalytic efficiency of the purified phospholipase A₂ is over two orders of magnitude less utilizing phosphatidylinositol substrate in comparison to phosphatidylethanolamine or phosphatidylcholine.

In that the activities of phospholipases A₂ are profoundly influenced by the interfacial characteristics of aggregate substrate, additional experiments were performed to compare hydrolysis of these individual classes of arachidonic acid containing phospholipids presented as substitutional impurities in vesicles comprised of binary mixtures of 10 mol% radiolabeled phosphatidylinositol, phosphatidylcholine, or phosphatidylethanolamine and 90 mol% unlabeled phosphatidylcholine (16:0, 20:4). The rank order of substrate class selectivity in this system was phosphatidylcholine > phosphatidylethanolamine > phosphatidylinositol (Table II). Thus, these results demonstrate that phosphatidylinositol is a suitable substrate for human myocardial phospholipase A₂ when presented in a physiologically relevant bilayer system possessing physiologically relevant surface charge and zwitterionic character (i.e., phosphatidylinositol was hydrolyzed at over one-half the rate observed for phosphatidylethanolamine in similar phosphatidylcholine matrices). The change in the relative rank order of substrate class selectivities (i.e., choline vs. ethanolamine glycerophospholipid) demonstrates that the physical state and interfacial characteristics of aggregate substrates are important

Table II. Human Myocardial Cytosolic Calcium-independent Phospholipase A₂ Class Specificity Assessed by Incorporating Radiolabeled Substrate as a Substitutional Impurity in a Phosphatidylcholine Matrix

<i>sn</i> -2 Radiolabeled glycerophospholipid	Fatty acid released (<i>pmol</i>)
Phosphatidylinositol	49
Phosphatidylcholine	115
Phosphatidylethanolamine	88

Fresh homogeneous myocardial cytosolic calcium-independent phospholipase A₂ (18 ng of the Mono-Q eluent) was incubated with the indicated class of radiolabeled glycerophospholipid (³H)arachidonic acid incorporated at the *sn*-2 position of each class incorporated as a 10 mol% impurity within a 100 μM bilayer matrix [bulk lipid concentration of phosphatidylcholine (16:0, 20:4)] for 60 s at 37°C. Released radiolabeled fatty acid was subsequently isolated after butanol extraction, separated by TLC, and quantified by scintillation spectrometry as described in Methods.




Figure 7. Lineweaver-Burk plot of the substrate concentration-velocity profiles of purified human myocardial cytosolic calcium-independent phospholipase A₂. Purified human myocardial phospholipase A₂ (ATP eluent 8,650-fold purified) was incubated with the indicated concentrations of *sn*-2 radiolabeled plasmenylcholine or phosphatidylcholine (containing either [³H]oleic or [³H]arachidonic acid at the *sn*-2 position as indicated) and reaction products were extracted with butanol, isolated by TLC, and quantified by scintillation spectrometry as described in Methods. Data points represent the mean of duplicate determinations. 16:0, [³H]18:1 phosphatidylcholine (○); 16:0, [³H]20:4 phosphatidylcholine (Δ); 16:0, [³H]18:1 plasmenylcholine (●); 16:0, [³H]20:4 plasmenylcholine (▲).

determinants of the catalytic efficiency of human myocardial calcium-independent phospholipase A₂.

To examine the subclass and molecular species specificities of the purified human myocardial phospholipase A₂, additional experiments were performed utilizing phosphatidylcholine and plasmenylcholine substrates containing either radiolabeled oleic acid or arachidonic acid at the *sn*-2 position and enzyme purified through the ATP column chromatographic step (8,600-fold purified). Comparisons of the relative rates of hydrolysis demonstrated that human myocardial phospholipase A₂ preferentially hydrolyzed vinyl ether containing choline glycerophospholipids (Fig. 7). Furthermore, plasmenylcholine substrate containing arachidonic acid at the *sn*-2 position was hydrolyzed over twofold more rapidly than plasmenylcholine substrate containing oleic acid at the *sn*-2 position. This contrasted with phosphatidylcholine molecular species containing either oleic or arachidonic acid at the *sn*-2 position which manifest similar rates of hydrolysis at each substrate concentration examined.

Identification of human myocardial choline and ethanolamine glycerophospholipid molecular species by reverse-phase HPLC and fast atom bombardment mass spectrometry. Because human myocardial phospholipase A₂ possesses a selectivity for plasmalogen substrate, the chemical identities of individual choline and ethanolamine glycerophospholipid molecular species in human myocardium were determined to document the presence of these substrates. Human myocardial phospholipids were extracted from ventricular tissue by the method of Bligh and Dyer (32) and individual phospholipid classes were purified by straight-phase HPLC as described in Methods. Re-




Figure 8. Reverse-phase HPLC of monobenzoate derivatives of ethanolamine and choline glycerophospholipids in human ventricular tissue. Human ventricular ethanolamine and choline glycerophospholipids were purified by straight-phase HPLC, hydrolyzed by *Bacillus cereus* phospholipase C, and derivatized to their monobenzoate derivatives as described in Methods. Individual molecular species were separated by reverse-phase HPLC utilizing an octadecyl silica column employing isocratic elution with acetonitrile/isopropanol (85/15, vol/vol) as the mobile phase. (A) Peaks from reverse-phase HPLC analysis of monobenzoate derivatives of ethanolamine glycerophospholipids were identified as follows: 18:1-20:4 phosphatidylethanolamine (1), 16:0-20:4 phosphatidylethanolamine (2), 18:1-20:4 plasmenylethanolamine (3), 16:0-20:4 plasmenylethanolamine (4), 18:0-20:4 phosphatidylethanolamine (5), 18:0-18:2 phosphatidylethanolamine (6), and 18:0-20:4 plasmenylethanolamine (7). (B) The peaks of individual molecular species of the monobenzoate derivatives of choline glycerophospholipids were identified as follows: 16:0-20:4 phosphatidylcholine (1), 18:1-18:2 phosphatidylcholine (2), 16:0-18:2 phosphatidylcholine and 16:0-20:4 plasmenylcholine (3), 18:0-20:4 phosphatidylcholine (4), 16:0-18:2 plasmenylcholine (5), 16:0-18:1 phosphatidylcholine (6), 16:0-16:0 phosphatidylcholine (7), 16:0-18:1 plasmenylcholine (8), 16:0-16:0 plasmenylcholine (9), and 18:0-18:1 phosphatidylcholine (10). Assignments of molecular species identities of derivatized ethanolamine and choline glycerophospholipids to each peak were determined by derivatizing eluents corresponding to each peak by acid methanolysis and subsequent analysis by capillary gas chromatography.

verse-phase HPLC of monobenzoate diradyl glycerol derivatives of human myocardial ethanolamine glycerophospholipids, as well as fast atom bombardment mass spectroscopic analysis of underivatized ethanolamine glycerophospholipids, revealed that plasmenylethanolamine is the predominant molecular subclass of human myocardial ethanolamine glycerophospholipids (Figs. 8A and 9A; Table III). Plasmenylethanolamine molecular species predominantly contained either 16:0, 18:0 or 18:1 vinyl ether aliphatic constituents at the *sn*-1 position and arachidonic acid at the *sn*-2 position (Figs. 8A and 9A; Table III). The predominant phosphatidylethanolamine

molecular species present in human myocardial ethanolamine glycerophospholipids contained stearic acid at the *sn*-1 position and arachidonic acid at the *sn*-2 position (Figs. 8A and 9A, Table III).

Reverse-phase HPLC of monobenzoate diradyl glycerol derivatives of human choline glycerophospholipids, as well as fast atom bombardment mass spectrometry of underivatized choline glycerophospholipids demonstrated that > 25% of the choline glycerophospholipids were composed of plasmalogen molecular species (Figs. 8B and 9B; Table III). Plasmenylcholine in human myocardium contained predominantly the vinyl




Figure 9. Fast atom bombardment mass spectrometry of human ventricular choline and ethanolamine glycerophospholipids. Straight-phase HPLC-purified (A) ethanolamine or (B) choline glycerophospholipids (~ 300 nmol) each were dissolved in 20 μ l of chloroform/methanol (1/1, vol/vol) and 2 μ l was subsequently mixed with ~ 3 μ l of glycerol on a copper probe. Fast atom bombardment mass spectrometry was performed as described in Methods. Protonated molecular species of ethanolamine glycerophospholipids from ventricular tissue

were identified as 16:0-20:4 plasmenylethanolamine (m/z = 724), 18:1-20:4 plasmenylethanolamine (m/z = 750), 18:0-20:4 plasmenylethanolamine (m/z = 752), and 18:0-20:4 phosphatidylethanolamine (m/z = 768). Protonated molecular species of choline glycerophospholipids were identified as 16:0-18:2 plasmenylcholine (m/z = 742), 16:0-18:1 plasmenylcholine (m/z = 744), 16:0-18:2 phosphatidylcholine (m/z = 758), 16:0-18:1 phosphatidylcholine (m/z = 760), 16:0-20:4 plasmenylcholine (m/z = 766) and 16:0-20:4 phosphatidylcholine (m/z = 782).

Table III. Choline and Ethanolamine Glycerophospholipid Molecular Species in Human Myocardium

Choline glycerophospholipids			Ethanolamine glycerophospholipids		
Molecular species (sn-1-sn-2)	FAB-MS %	RP-HPLC %	Molecular species (sn-1-sn-2)	FAB-MS %	RP-HPLC %
16:0-18:1(D)	34	27	16:0-20:4(D)	4	6
16:0-18:2(D)	29	23*	16:0-20:4(P)	19	20
16:0-20:4(D)	12	12	18:1-20:4(D)	3	3
16:0-18:1(P)	6	3	18:1-20:4(P)	18	17
16:0-18:2(P)	7	7	18:0-20:4(D)	36	36
16:0-20:4(P)	12	15*	18:0-18:2(D)	2	3
18:1-18:2(D)	ND	4	18:0-20:4(P)	21	15
18:1-20:4(D)	ND	2			
18:0-18:1(D)	ND	2			
18:0-20:4(D)	ND	5			

Purified choline and ethanolamine glycerophospholipids were analyzed by either fast atom bombardment-mass spectrometry (FAB-MS) (ion peaks were quantified by their integrated intensity) or by reverse-phase high pressure liquid chromatography (RP-HPLC) of their monobenzoate diradyl glycerol derivatives (UV absorbing peaks (231 nm) were quantitated by integration). P, D, and ND indicate plasmalogen molecular species, diacyl molecular species, and not detectable, respectively. * Values were determined by collecting the RP-HPLC peak containing both 16:0-18:2(D) and 16:0-20:4(P) monobenzoate diradyl glycerols and analyzing acid methanolysis derivative products from the RP-HPLC peak by capillary gas chromatography.

ether of palmitaldehyde at the *sn*-1 position with arachidonic > linoleic > oleic acid at the *sn*-2 position (Figs. 8 B and 9 B; Table III). Phosphatidylcholine molecular species in human myocardial choline glycerophospholipids contained palmitic acid at the *sn*-1 position and, conversely, arachidonic < linoleic < oleic acid at the *sn*-2 position (Figs. 8 B and 9 B; Table III). These results demonstrate the predominance of plasmalogens in the ethanolamine glycerophospholipid pool and the abundance of vinyl ether linkages in choline glycerophospholipid molecular species in human myocardium.

Discussion

The relationship of accelerated phospholipid catabolism during myocardial ischemia to the pathophysiologic sequelae of myocardial infarction has been an area of extensive investigation during the last decade. A multiplicity of experimental animal and cell culture models has been employed to study the potential relevance of the activation of phospholipases to the electrophysiologic dysfunction and myocytic cellular necrosis manifest during human myocardial infarction. During the course of these studies, a large diversity of mammalian phospholipases has been identified and an intriguing heterogeneity of individual phospholipid constituents in myocardium from many different species has been documented. Specifically, in several animal species (e.g., dog and rabbit) plasmalogens are the predominant phospholipid constituent of critical subcellular membranes (e.g., sarcolemma and sarcoplasmic reticulum) (22, 23), and plasmalogen-selective phospholipase A₂ are the major measurable phospholipase activity in many tissues (13, 17, 20). Despite substantial evidence implicating the importance of plasmalogen catabolism during ischemic and reperfusion injury (13, 14, 36-38), the purification of human myocar-

dial phospholipase A₂ and the chemical identification of the individual molecular species of human myocardial phospholipids have not been forthcoming. Herein we demonstrate that the major isoform of human myocardial cytosolic calcium-independent phospholipase A₂ activity is a 40-kD polypeptide (similar to that found in other mammalian species such as canine and rabbit myocardium) (13, 20) and that plasmenylcholine and plasmenylethanolamine molecular species enriched in arachidonic acid represent prominent chemical constituents of human myocardial phospholipids.

The purification strategy for this human myocardial phospholipase A₂ exploited the previously identified affinity interaction between cytosolic calcium-independent phospholipase A₂ and ATP (39) which facilitated the 182,000-fold purification of the human myocardial enzyme in 38% overall yield. During the course of the purification, evidence for the presence of functionally distinct isoforms of calcium-independent phospholipase A₂ was uncovered. In contrast to previous experimental results in both canine and rabbit myocardium, human myocardium contained a calcium-independent phospholipase A₂ activity which required high salt for elution from the anion exchange matrix and possessed distinct physical and kinetic properties. Although the major phospholipase A₂ isoform selectively hydrolyzed plasmalogen substrate, possessed a pH optimum of 7.0, and was relatively stable, the minor isoform (eluting at high NaCl concentrations) hydrolyzed plasmenylcholine and phosphatidylcholine substrates at similar rates, possessed a pH optimum of 8.5 and was markedly labile. Although definitive identification of the presence of two separate phospholipase A₂ gene products requires sequence determination and detailed chemical analyses of both isoforms, the present results identify the existence of two functionally distinct calcium-independent phospholipase A₂ activities in human myocardium. The precise chemical differences underlying these functional alterations remain unknown at present.

Kinetic analyses of the class, subclass and molecular species specificities of the purified human myocardial phospholipase A₂ in multiple systems demonstrated that plasmalogens containing arachidonic acid at the *sn*-2 position are the preferred substrates. Accordingly, the molecular species distribution of phospholipids in human myocardium was analyzed by two independent methods to document the presence of plasmalogens and to identify the relative content of individual molecular species containing arachidonic acid. Substantial amounts of plasmalogen and plasmalogen molecular species containing arachidonic acid were identified in human myocardium. These results represent the first identification of the individual molecular species distribution of phospholipids in human myocardium. The abundance of plasmalogen molecular species in human myocardium resembles that found in canine, rabbit and hamster myocardium and exceeds that present in rat or guinea pig myocardium (22–27).

Conclusion. These results represent the first reported isolation of calcium-independent phospholipase A₂ and its purification to apparent-homogeneity from intact human tissue. They further underscore the potential significance of calcium-independent phospholipases A₂ as the enzymic mediators of ischemia-induced phospholipolysis because this class of enzymes constitutes the overwhelming majority of measurable phospholipase activity in human myocardium. Accordingly, human myocardial cytosolic calcium-independent phospholipases A₂ represent an attractive target for pharmacologic attenuation of ischemic membrane dysfunction in compromised myocardium. Mechanism-based discrimination between calcium-dependent and calcium-independent phospholipases A₂ employing suicide inhibition has recently been reported (40). The development of isoform-specific calcium-independent phospholipase A₂ inhibitors which achieve their selectivity by exploiting the chemical determinants responsible for the distinct substrate specificities exhibited by calcium-independent phospholipase A₂ isoforms should facilitate the development of selective agents capable of attenuating membrane dysfunction during myocardial ischemia.

Acknowledgments

We would like to acknowledge the sustained efforts of Dr. Jeffrey Saffitz in the procurement of human ventricular myocardium for these studies. We also thank Rayna Hollenback for assistance in the preparation of this manuscript.

This research was supported by grant 34839 from the National Institutes of Health.

References

1. Samuelsson, B., M. Goldyne, E. Granstrom, M. Hamberg, S. Hammarstrom, and C. Malmsten. 1978. Prostaglandins and thromboxanes. *Annu. Rev. Biochem.* 47:997–1029.
2. Wykle, R. L., B. Malone, and F. Snyder. 1980. Enzymatic synthesis of 1-alkyl-2-acetyl-*sn*-glycero-3-phosphocholine, a hypotensive and platelet-aggregating lipid. *J. Biol. Chem.* 255:10256–10260.
3. Dennis, E. A. 1983. Phospholipases. In *Enzymes*, 3rd edition. P. D. Boyer, editor. Academic Press, Inc., New York. 307–353.

4. Berridge, M. J., and R. F. Irvine. 1989. Inositol phosphates and cell signaling. *Nature (Lond.)* 341:197–205.
5. Katz, A. M., and F. C. Messineo. 1981. Lipid-membrane interactions and the pathogenesis of ischemic damage in the myocardium. *Circ. Res.* 48:1–16.
6. Corr, P. B., R. W. Gross, and B. E. Sobel. 1984. Amphipathic metabolites and membrane dysfunction in ischemic myocardium. *Circ. Res.* 55:135–154.
7. Needleman, P., J. Turk, B. A. Jakschik, A. R. Morrison, and J. B. Lefkowitz. 1986. Arachidonic acid metabolism. *Annu. Rev. Biochem.* 55:69–102.
8. van Bilsen, M., G. J. van der Vusse, P. H. M. Willemsen, W. A. Coumans, T. H. M. Roemen, and R. S. Reneman. 1989. Lipid alterations in isolated, working rat hearts during ischemia and reperfusion: its relation to myocardial damage. *Circ. Res.* 64:304–314.
9. Hazen, S. L., and R. W. Gross. 1991. Principles of membrane biochemistry and their application to the pathophysiology of cardiovascular disease. In *The Heart and Cardiovascular System*, 2nd edition. H. Fozzard, editor. Raven Press, New York. 839–860.
10. Chien, K. R., J. B. Reeves, L. M. Buja, F. Bonte, R. W. Tarkey, and J. T. Willerson. 1981. Phospholipid alterations in canine ischemic myocardium: temporal and topographical correlations with Tc-99m-PPI accumulation and an *in vitro* sarcolemmal Ca²⁺ permeability defect. *Circ. Res.* 48:711–719.
11. G. J. van der Vusse, T. H. M. Roemen, F. W. Prinven, W. A. Coumans, and R. S. Reneman. 1982. Uptake and tissue content of fatty acids in dog myocardium under normoxic and ischemic conditions. *Circ. Res.* 50:538–546.
12. Das D. K., R. M. Engelman, J. A. Rousou, R. H. Breyer, H. Otani, and S. Lemeshow. 1986. Role of membrane phospholipids in myocardial injury induced by ischemia and reperfusion. *Am. J. Physiol.* 251:H71–H79.
13. Hazen, S. L., D. A. Ford, and R. W. Gross. 1991. Activation of a membrane-associated phospholipase A₂ during rabbit myocardial ischemia which is highly selective for plasmalogen substrate. *J. Biol. Chem.* 266:5629–5633.
14. Ford, D. A., S. L. Hazen, J. E. Saffitz, and R. W. Gross. 1991. The rapid and reversible activation of a calcium-independent plasmalogen-selective phospholipase A₂ during myocardial ischemia. *J. Clin. Invest.* 88:331–335.
15. Gross, R. W. 1992. Myocardial phospholipases A₂ and their membrane substrates. *Trends Cardiovasc. Med.* 2:115–121.
16. Tam, S. W., R. Y. K. Man, and P. C. Choy. 1984. The hydrolysis of phosphatidylcholine by phospholipase A₂ in hamster heart. *Can. J. Biochem. Cell Biol.* 62:1269–1274.
17. Wolf, R. A., and R. W. Gross. 1985. Identification of neutral active phospholipase C which hydrolyzes choline glycerophospholipids and plasmalogen selective phospholipase A₂ in canine myocardium. *J. Biol. Chem.* 260:7295–7303.
18. Nalbhone, G., and K. Y. Hostetler. 1985. Subcellular localization of the phospholipases A of rat heart: evidence for a cytosolic phospholipase A₁. *J. Lipid Res.* 26:104–114.
19. Cao, Y., S. W. Tam, G. Arthur, H. Chen, and P. C. Choy. 1987. The purification and characterization of a phospholipase A in hamster heart cytosol for the hydrolysis of phosphatidylcholine. *J. Biol. Chem.* 262:16927–16935.
20. Hazen, S. L., R. J. Stuppy, and R. W. Gross. 1990. Purification and characterization of canine myocardial cytosolic phospholipase A₂: a calcium-independent phospholipase with absolute *sn*-2 regioselectivity for diradyl glycerophospholipids. *J. Biol. Chem.* 265:10622–10630.
21. Hazen, S. L., and R. W. Gross. 1992. Identification and characterization of human myocardial phospholipase A₂ from transplant recipients suffering from end-stage ischemic heart disease. *Circ. Res.* 70:486–495.
22. Gross, R. W. 1984. High plasmalogen and arachidonic acid content of canine myocardial sarcolemma: a fast atom bombardment mass spectroscopic and gas chromatography-mass spectroscopic characterization. *Biochemistry.* 23:158–165.
23. Gross, R. W. 1985. Identification of plasmalogen as the major phospholipid constituent of cardiac sarcoplasmic reticulum. *Biochemistry.* 24:1662–1668.
24. Osanai, A., and T. Sakagami. 1979. Compositions of diacyl-, alkenyl-acyl-, and alkyl-acyl-glycerophosphorylcholine and -ethanolamine in male and female rabbit hearts. *J. Biochem.* 85:1453–1459.
25. Arthur, G., L. Covic, M. Wientzek, and P. C. Choy. 1985. Plasmalogenase in hamster heart. *Biochim. Biophys. Acta.* 833:189–195.
26. Nakagawa, Y., K. Waku, and Y. Ishima. 1982. Changes in the composition of fatty chains of diacyl, alkylacyl and alkenylacyl ethanolamine and choline phosphoglycerides during the development of chick heart ventricular cells. *Biochim. Biophys. Acta.* 712:667–676.
27. Rabinowitz, J. L., and E. S. Hercker. 1976. Total plasmalogens and 0-(acylalkylglycerophosphoryl)ethanolamine from labelled hexadecanol and palmitate during hypoxia and anoxia in rat heart. *Biochem. J.* 160:463–466.
28. Hazen, S. L., L. A. Zupan, and R. W. Gross. 1991. Purification and characterization of novel cytosolic phospholipase A₂ activities from canine myocardium and sheep platelets. *Methods Enzymol.* 197:400–411.
29. Han, X., L. A. Zupan, S. L. Hazen, and R. W. Gross. 1992. Semisynthesis and purification of homogeneous plasmalogen molecular species. *Anal. Biochem.* 200:119–124.

30. Creer, M. H., and R. W. Gross. 1985. Reverse-phase high-performance liquid chromatographic separation of molecular species of alkyl ether, vinyl ether and monoacyl lysophospholipids. *J. Chromatogr.* 338:61-69.
31. Ayanoglu, E., A. Wegmann, O. Pilet, G. D. Marbury, J. R. Hass, and C. Djerassi. 1984. Mass spectrometry of phospholipids: some applications of desorption, chemical ionization and fast atom bombardment. *J. Am. Chem. Soc.* 106:5246-5251.
32. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purification. *Can. J. Biochem. Physiol.* 37:911-917.
33. Ford, D. A., and R. W. Gross. 1989. Plasmeneylethanolamine is the major storage depot for arachidonic acid in rabbit vascular smooth muscle and is rapidly hydrolyzed after angiotensin II stimulation. *Proc. Natl. Acad. Sci. USA.* 86:3479-3483.
34. Blank, M. L., E. A. Cress, and F. Snyder. 1987. Separation and quantitation of phospholipid subclasses as their diradyl glycerobenzoate derivatives by normal-phase high-performance liquid chromatography. *J. Chromatogr.* 392:421-425.
35. Lohner, K., A. Hermetter, and F. Paltauf. 1984. Phase behavior of ethanolamine plasmalogen. *Chem. Phys. Lipids.* 34:163-170.
36. Chien, K. R., A. Han, A. Sen, L. M. Buja, J. T. Willerson. 1984. Accumulation of unesterified arachidonic acid in ischemic canine myocardium: relationship to a phosphatidylcholine deacylation-reacylation cycle and the depletion of membrane phospholipids. *Circ. Res.* 54:313-322.
37. Miyazaki, Y., R. W. Gross, B. E. Sobel, and J. E. Saffitz. 1987. Biochemical and subcellular distribution of arachidonic acid in rat myocardium. *Am. J. Physiol.* 253:C846-C853.
38. Miyazaki, Y., R. W. Gross, B. E. Sobel, and J. E. Saffitz. 1990. Selective turnover of sarcolemmal phospholipids during lethal cardiac myocyte injury. *Am. J. Physiol.* 259:C325-C331.
39. Hazen, S. L., and R. W. Gross. 1991. ATP-dependent regulation of rabbit myocardial cytosolic calcium-independent phospholipase A₂. *J. Biol. Chem.* 266:14526-14534.
40. Hazen, S. L., L. A. Zupan, R. H. Weiss, D. P. Getman, and R. W. Gross. 1991. Suicide inhibition of canine myocardial cytosolic calcium-independent phospholipase A₂. *J. Biol. Chem.* 266:7227-7232.